Related Experiment Videos
LDL-cholesterol lowering and atherosclerosis--clinical benefit and possible mechanisms: an update
1Department of Medicine, University Hospital Nijmegen, The Netherlands.
Insights
Potent cholesterol-lowering drugs significantly reduce coronary events in patients with high cholesterol. This review covers effective low-density lipoprotein treatments and their role in preventing cardiovascular disease.
Area of Science:
- Cardiology
- Pharmacology
- Preventive Medicine
Background:
- The lipid hypothesis, linking cholesterol to heart disease, is supported by recent clinical trials.
- Elevated cholesterol levels are a significant risk factor for coronary events.
Purpose of the Study:
- To review potent low-density lipoprotein cholesterol-lowering treatments.
- To discuss advancements in hypolipidemic therapy.
- To summarize mechanisms of cholesterol reduction in atherosclerosis.
Main Methods:
- Review of recent lipid-lowering randomized trials.
- Analysis of primary and secondary prevention studies.
- Synthesis of data on hypolipidemic drug efficacy.
Main Results:
- Potent lipid-lowering drugs substantially reduce coronary event risk.
- Effective cholesterol reduction is confirmed in both symptomatic and asymptomatic patients.
- Evidence supports the role of cholesterol reduction in preventing atherosclerosis.
Conclusions:
- Lipid-lowering therapy is crucial for managing cardiovascular risk.
- Advancements in hypolipidemic drugs offer improved patient outcomes.
- Understanding cholesterol metabolism is key to preventing atherosclerotic progression.
Abstract:
The results of several lipid-lowering randomized trials have been released during the past years and have confirmed the lipid hypothesis. Reduction of cholesterol by potent drugs in clinically symptomatic or asymptomatic patients with above-average cholesterol levels will substantially reduce the risk of coronary events. The present article gives a review of potent low-density lipoprotein cholesterol-lowering treatments and discusses developments in hypolipidaemic therapy in relation to recent primary and secondary prevention studies. In addition, possible mechanisms of cholesterol lowering in retardation of the atherosclerotic process are summarised.